Amgen has recently projected robust revenue growth for 2025, forecasting total revenues between $34.3 billion and $35.7 billion with adjusted earnings per share ranging from $20.00 to $21.20. This positive outlook comes as the company continues to advance its extensive product pipeline and expand into new therapeutic areas.
Key drivers influencing Amgen's anticipated growth include several innovative therapies. The cholesterol-lowering drug Repatha, osteoporosis treatment EVENITY, and severe asthma therapy TEZSPIRE are all expected to contribute significantly to Amgen’s revenue. Furthermore, the company's oncology portfolio, rare disease treatments, and the launch of new biosimilars should bolster earnings. According to longportapp.com, Amgen's biosimilar portfolio, in particular, experienced a 16% increase in 2024, contributing to its optimistic outlook.
Amgen's strategic interests also reflect heavy investment in research and development, with a planned increase of approximately 15% in R&D spending year-over-year. The focus will be on advancing therapies like MariTide, an obesity treatment preparing for Phase 3 trials in early 2025, as mentioned by Amgen. Additionally, Amgen has announced a significant $900 million expansion of its biotech manufacturing facility in Ohio, a move that Reuters reports will generate 750 new jobs and increase its total investment in the region to over $1.4 billion.